


THERE, TOGETHER WHEN IT COUNTS



A HUMAN

RESPONSE

Online Help



Your Board



Scott St John



Lewis Gradon



Sir Michael Daniell



Pip Greenwood



Geraldine McBride



Neville Mitchell



Donal O'Dwyer



Agenda

- Chair's Address and Board Subcommittee Updates
- Managing Director and Chief Executive Officer's Review
- Financial Statements
- Resolutions
- Voting
- General Questions



FY2021 Financial Highlights

Operating Revenue

\$1.97_B

1 56%

Net Profit After Tax

\$524.2м


182%

Dividend

38.00cps 1 38%



FY2021 Revenue by Product Group









Hospital Product Group

FY21 Result

Revenue

\$1.5B

FY21 Revenue Growth

NZ\$

87%

Constant Currency

1 94%









Homecare Product Group

FY21 Result

Revenue


\$466M

FY21 Revenue Growth

NZ\$

Constant Currency 2%


1 4%





Gross and Operating Margins





— — Long Term Gross Margin Target – 65%

Operating (EBIT) Margin



Long Term Operating Margin Target - 30%





Research and development - \$136.7 million investment





Fisher & Paykel HEALTHCARE



Profit-sharing bonus - \$29 million



Community

Fisher & Paykel Healthcare Foundation

NZ \$20 MILLION



FY22 Trading Update

First four months of FY22

- Revenue \$583M, 2% below the prior comparable period in constant currency
- Hospital product group
 - Revenue down 3% cc from prior comparable period
 - 13% decline in hardware sales from prior comparable period
 - Hardware revenue remained elevated
 - Consumables revenue +2% CC*
 - New applications consumables +17% CC*
- Homecare product group
 - Revenue +4% CC* from prior comparable period
 - 4% growth in OSA masks



Outlook for the remainder of FY22

For the remainder of the 2022 financial year*:

- No quantitative guidance provided given continuing uncertainties related to COVID-19
- Hospital hardware revenue not expected to continue at elevated levels
- Hospital consumables sales will continue to be impacted by COVID-19 hospitalisation rates
- New OSA patient diagnosis rates expected to be at or above FY21 rates
- Freight costs remain elevated
- Continue to grow investment in R&D and SG&A



^{*} Based on observations and expectations as at 18 August 2021

Financial Statements

- Opportunity for shareholders to ask any questions specifically on the financial statements, the auditor's report or the company's 2021 annual report.
- There will be an opportunity to ask any general questions once all items on the agenda have been considered.






Resolutions

- 1. Re-election of Scott St John as Director
- 2. Re-election of Sir Michael Daniell as Director
- 3. Auditor's Remuneration
- 4. Issue of Performance Share Rights
- 5. Issue of Options




How to Vote Online



Resolution 1: Re-election of Scott St John

That Scott St John, who retires by rotation and, being eligible, offers himself for reelection, be re-elected as a director of the Company.



Click "Submit Vote" to lodge your vote.

Need help?

Call the Link Market Services helpline

0800 200 220



Resolution 2: Re-election of Sir Michael Daniell

That Sir Michael Daniell, who retires by rotation and, being eligible, offers himself for re-election, be re-elected as a director of the Company.



Click "Submit Vote" to lodge your vote.

Need help?

Call the Link Market Services helpline
0800 200 220



Resolution 3: Auditor's Remuneration

That the Directors be authorised to fix the

fees and expenses of PwC as the

Company's auditor.

Click "Submit Vote" to lodge your vote.

Need help?

Call the Link Market Services helpline 0800 200 220



Resolution 4: Issue of Performance Share Rights

That approval be given for the issue of up

to 60,000 performance share rights under

the Fisher & Paykel Healthcare

Performance Share Rights Plan to

Lewis Gradon, Managing Director and

Chief Executive Officer of the Company.

Click "Submit Vote" to lodge your vote.

Need help?

Call the Link Market Services helpline 0800 200 220



Resolution 5: Issue of Options

That approval be given for the issue of up

to 190,000 options under the

Fisher & Paykel Healthcare 2019 Share

Option Plan to Lewis Gradon, Managing

Director and Chief Executive Officer of the

Company.

Click "Submit Vote" to lodge your vote.

Need help?

Call the Link Market Services helpline 0800 200 220







This concludes the 2021 Annual Shareholders' Meeting.

Thank you for attending.

